

Patent  
Attorney's Docket No. 001560-390

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of	)	
	)	
Harukazu FUKAMI et al	)	Group Art Unit: 1624
	)	
Application No.: 09/763,213	)	Examiner: To be assigned
	)	
Filed: February 20, 2001	)	
	)	
For: DESCRIPTION QUINAZOLINE	)	
DERIVATIVES AND	)	
PHARMACEUTICAL APPLICATIONS	)	
THEREOF	)	

**AMENDMENT/REPLY TRANSMITTAL LETTER**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Enclosed is a Supplemental Preliminary Amendment for the above-identified patent application.

- ☐ A Petition for Extension of Time is also enclosed.
- ☐ A Terminal Disclaimer and a check for ☐ \$55.00 (248) ☐ \$110.00 (148) to cover the requisite Government fee are also enclosed.
- ☐ Also enclosed is \_\_\_\_\_
- ☐ Small entity status is hereby claimed.
- ☐ Applicant(s) request continued examination under 37 C.F.R. § 1.114 and enclose the ☐ \$355.00 (279) ☐ \$710.00 (179) fee due under 37 C.F.R. § 1.17(e).
- ☐ Applicant(s) previously submitted \_\_\_, on \_\_\_, for which continued examination is requested.
- ☐ Applicant(s) request suspension of action by the Office until at least \_\_\_, which does not exceed three months from the filing of this RCE, in accordance with 37 C.F.R. § 1.103(c). The required fee under 37 C.F.R. § 1.17(i) is enclosed.
- ☐ A Request for Entry and Consideration of Submission under 37 C.F.R. § 1.129(a) (146/246) is also enclosed.
- ☒ No additional claim fee is required.
- ☐ An additional claim fee is required, and is calculated as shown below:

## Amendment/Reply Transmittal Letter

Application No. 09/763.213Attorney's Docket No. 001560-390

Page 2

AMENDED CLAIMS					
	No. OF CLAIMS	HIGHEST NO. OF CLAIMS PREVIOUSLY PAID FOR	EXTRA CLAIMS	RATE	ADDT'L FEE
Total Claims		MINUS =		× \$18.00 (103) =	
Independent Claims		MINUS =		× \$80.00 (102) =	
If Amendment adds multiple dependent claims, add \$270.00 (104)					
Total Amendment Fee					
If small entity status is claimed, subtract 50% of Total Amendment Fee					
<b>TOTAL ADDITIONAL FEE DUE FOR THIS AMENDMENT</b>					

☐ A claim fee in the amount of \$\_\_\_\_\_ is enclosed.

☐ Charge \$\_\_\_\_\_ to Deposit Account No. 02-4800.

The Commissioner is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17, 1.20(d) and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By:

*Donna M. Meuth*  
Donna M. Meuth  
Registration No. 36,607

Reg No 32,747 for

P.O. Box 1404  
Alexandria, Virginia 22313-1404  
(703) 836-6620

Date: May 30, 2001

**CERTIFICATE OF FACSIMILE TRANSMITTAL**

I hereby certify that this Amendment/Reply Transmittal is being filed in the U.S. Patent and Trademark Office, together with the attached Supplemental Preliminary Amendment, on the date shown below.

*Amy Scipione*  
Amy Scipione

*5/30/01*  
Date

Patent

Attorney's Docket No. 001560-390#6B  
PS 6/11/01**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of )

Harukazu FUKAMI et al )

Group Art Unit: 1624

Application No.: 09/763,213 )

Prior Examiner: To be assigned

Filed: February 20, 2001 )

For: DESCRIPTION QUINAZOLINE )  
DERIVATIVES AND )  
PHARMACEUTICAL )  
APPLICATIONS THEREOF )**SUPPLEMENTAL PRELIMINARY AMENDMENT**Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Applicants filed a Preliminary Amendment on February 20, 2001. In accordance with the new PTO rules and procedures, applicants provide herewith a clean set of claims, as well as a marked-up copy.

**IN THE CLAIMS**

Please replace claims 3-6 as follows.

3. (Amended) A quinazoline derivative or a pharmaceutically acceptable salt thereof as claimed in claim 1, wherein, in the formula (1), R<sup>2</sup> is a carboxylic acid group or a hydrogen atom.

(10/00)